Finoriq research workspace
Acrivon Therapeutics, Inc. (ACRV) SEC Filings & Filing Highlights
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops. Review ACRV SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
- Company
- Acrivon Therapeutics, Inc. (ACRV)
- Ticker
- ACRV
- Market Cap
- $74M
- Latest Price
- $1.73
- Industry
- Biotech & Pharma
Acrivon Therapeutics, Inc. (ACRV) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Acrivon Therapeutics, Inc. (ACRV).
| Event | Form | Date |
|---|---|---|
| Three items of business were acted upon by the stockholders at the Annual Meeting. The final re...At the Annual Meeting, a quorum of 31,336,993.43 shares of the Company’s common stock, or 73.21% of the outstanding shares of common stock... | 8-K5.07 | 2026-06-17 |
| On June 17, 2026, Acrivon Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of st...On June 17, 2026, Acrivon Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). At the An... | 8-K5.02 | 2026-06-17 |
| Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 C...Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts | 8-K2.02 | 2026-05-13 |
| Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Bus...Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | 8-K7.01 | 2026-03-19 |
| Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Bus...Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | 8-K2.02 | 2026-03-19 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.